Rockwell Medical (RMTI) Gets FDA Approval of Triferic
In news out in pre-market, Rockwell Medical (RMTI) received FDA approval of Triferic, a new drug that delivers iron to the bone marrow via dialysate in a non-invasive manner to treat iron-deficiency anemia in End Stage Renal Disease patients.
End Stage Renal Disease affects 2.52 million patients globally and is growing 6-8% annually, exceeding population growth rates in much of the world.
Rockwell is also planning to develop new brand extensions based on Triferic to treat other iron-deficiency anemia indications including: stages 3 and 4 chronic kidney disease, oncology, women’s health, pre-mature babies, gastroenterology and parenteral nutrition, as well as new drugs for other targeted renal therapies and indications.
The average analyst estimate for 2015 is for 85% revenue growth yoy and EPS to turn a positive .25/share.
|Rockwell Medical Estimates||Year Ending December 2014||Year Ending December 2015|
|Avg. EPS Estimate||-0.47||0.25|
|No. of Analysts||5.00||5.00|
|Avg. Revenue Estimate||52.79M||97.94M|
|No. of Analysts||5||6|
Most recent coverage from Oppenheimer on January 6, with a $24/share price target.
Rockwell will be introducing Triferic in presentations to nephrologists at the Annual Dialysis Conference January 31 – February 3, 2015.
For more on Rockwell Medical, see: Rockwell Medical (RMTI) Speculative Buy as January PDUFA Date Nears
Congratulations to our subscribers who invested with us in RMTI at 12 month lows in December!
Subscribe to MicrocapResearch.com now and discover the next great microcap stock.
Follow MicrocapResearch.com on Twitter:
Disclosure: The publishers of MicrocapResearch.com are long shares of Rockwell Medical.